Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.35 |
| ▸ | FEN1 | P39748 | 5/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 2/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902833 | 0.88 | CYP1A1 (0.41) | CYP1A2CYP1A1CYP1B1LATS1LATS2 | |
| SCHEMBL11903363 | 0.84 | CYP1A1 (0.39) | CYP1A2CYP1A1CYP1B1GRM1LATS1 | |
| SCHEMBL867664 | 0.82 | MPL (0.44) | ALOX5APFEN1GRIN1GRIN2B | |
| SCHEMBL11903373 | 0.82 | CYP1A1 (0.39) | CYP1A2CYP1A1CYP1B1GRM1LATS1 | |
| SCHEMBL11902852 | 0.81 | MAP4K4 (0.33) | CYP1A2CYP1A1CYP1B1MAP4K4ALOX5AP | |
| SCHEMBL11903355 | 0.77 | NPC1 (0.51) | CYP1A2CYP1A1CYP1B1ADORA1 | |
| SCHEMBL868406 | 0.74 | EGFR (0.45) | CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL17476606 | 0.71 | NPC1 (0.35) | CYP1A2CYP1A1CYP1B1ALOX5APFEN1 | |
| SCHEMBL869532 | 0.70 | ABCG2 (0.42) | CYP1A2MAP4K4ADORA2AADORA1CYP3A4 | |
| SCHEMBL11902885 | 0.68 | ERBB2 (0.47) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | CYP1A2 1095/4885CYP1A1 719/4885CYP1B1 538/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | CYP1A2 1075/4885CYP1A1 652/4885CYP1B1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.